EyePoint Pharmaceuticals, Inc.

Contributing Author

Recent Articles by EyePoint Pharmaceuticals, Inc.

Jun-16	EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
May-28	EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
May-27	EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU for Treatment of Wet Age-Related Macular Degeneration EYPT GlobeNewswire
May-16	EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) EYPT GlobeNewswire
May-13	EyePoint Announces Participation at Upcoming Investor Conferences EYPT GlobeNewswire
May-07	EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments EYPT GlobeNewswire